blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2035417

EP2035417 - BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.01.2012
Database last updated on 31.08.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2009/12]
Inventor(s)01 / BIRCH, Alan Martin
AstraZeneca R & D Alderley Alderley Park
Macclesfield Cheshire SK10 4TG / GB
02 / BUTLIN, Roger John
AstraZeneca R & D Alderley Alderley Park
Macclesfield Cheshire SK10 4TG / GB
03 / PLOWRIGHT, Alleyn
AstraZeneca R & D Mölndal
431 83 Mölndal / SE
 [2009/12]
Representative(s)Berry, Ian Gordon
AstraZeneca AB Global Intellectual Property
151 85 Södertälje / SE
[2009/12]
Application number, filing date07733082.706.06.2007
[2009/12]
WO2007GB02070
Priority number, dateUS20060811895P08.06.2006         Original published format: US 811895 P
[2009/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2007141517
Date:13.12.2007
Language:EN
[2007/50]
Type: A1 Application with search report 
No.:EP2035417
Date:18.03.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 13.12.2007 takes the place of the publication of the European patent application.
[2009/12]
Type: B1 Patent specification 
No.:EP2035417
Date:02.03.2011
Language:EN
[2011/09]
Search report(s)International search report - published on:EP13.12.2007
ClassificationIPC:C07D413/04, C07D413/14, A61K31/4245, A61P3/10
[2009/12]
CPC:
C07D413/04 (EP,KR,US); A61K31/4245 (KR); A61P1/04 (EP);
A61P13/12 (EP); A61P15/08 (EP); A61P17/02 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P19/10 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P3/00 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/10 (EP); A61P31/18 (EP);
A61P37/02 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/04 (EP); A61P9/08 (EP); A61P9/10 (EP);
C07D413/14 (EP,KR,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/12]
Extension statesALNot yet paid
BANot yet paid
HR08.01.2009
MKNot yet paid
RSNot yet paid
TitleGerman:BENZIMIDAZOLE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON DIABETES[2009/12]
English:BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES[2009/12]
French:BENZIMIDAZOLES ET LEUR APPLICATION AU TRAITEMENT DU DIABÈTE[2009/12]
Entry into regional phase08.01.2009National basic fee paid 
08.01.2009Designation fee(s) paid 
08.01.2009Examination fee paid 
Examination procedure08.01.2009Examination requested  [2009/12]
23.03.2010Despatch of a communication from the examining division (Time limit: M04)
28.06.2010Reply to a communication from the examining division
18.10.2010Communication of intention to grant the patent
20.01.2011Fee for grant paid
20.01.2011Fee for publishing/printing paid
Opposition(s)05.12.2011No opposition filed within time limit [2012/06]
Fees paidRenewal fee
30.06.2009Renewal fee patent year 03
30.06.2010Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT02.03.2011
BE02.03.2011
CY02.03.2011
CZ02.03.2011
DK02.03.2011
EE02.03.2011
FI02.03.2011
HU02.03.2011
LT02.03.2011
LV02.03.2011
MT02.03.2011
PL02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
GR03.06.2011
IE06.06.2011
LU06.06.2011
MC30.06.2011
IS02.07.2011
PT04.07.2011
[2013/45]
Former [2013/25]AT02.03.2011
BE02.03.2011
CY02.03.2011
CZ02.03.2011
DK02.03.2011
EE02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
MT02.03.2011
PL02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
GR03.06.2011
IE06.06.2011
LU06.06.2011
MC30.06.2011
IS02.07.2011
PT04.07.2011
Former [2013/21]AT02.03.2011
BE02.03.2011
CY02.03.2011
CZ02.03.2011
DK02.03.2011
EE02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
MT02.03.2011
PL02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
GR03.06.2011
IE06.06.2011
MC30.06.2011
IS02.07.2011
PT04.07.2011
Former [2012/20]AT02.03.2011
BE02.03.2011
CY02.03.2011
CZ02.03.2011
DK02.03.2011
EE02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
MT02.03.2011
PL02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
GR03.06.2011
IE06.06.2011
IS02.07.2011
PT04.07.2011
Former [2012/12]AT02.03.2011
BE02.03.2011
CY02.03.2011
CZ02.03.2011
DK02.03.2011
EE02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
MT02.03.2011
PL02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
GR03.06.2011
IS02.07.2011
PT04.07.2011
Former [2012/05]AT02.03.2011
BE02.03.2011
CY02.03.2011
CZ02.03.2011
EE02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
MT02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
GR03.06.2011
IS02.07.2011
PT04.07.2011
PL20.07.2011
Former [2011/50]AT02.03.2011
BE02.03.2011
CY02.03.2011
CZ02.03.2011
EE02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
GR03.06.2011
IS02.07.2011
PT04.07.2011
PL20.07.2011
Former [2011/49]AT02.03.2011
BE02.03.2011
CY02.03.2011
CZ02.03.2011
EE02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
GR03.06.2011
PT04.07.2011
Former [2011/47]AT02.03.2011
BE02.03.2011
CY02.03.2011
EE02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
SI02.03.2011
BG02.06.2011
GR03.06.2011
PT04.07.2011
Former [2011/41]AT02.03.2011
BE02.03.2011
CY02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
SI02.03.2011
BG02.06.2011
GR03.06.2011
Former [2011/38]AT02.03.2011
CY02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
SI02.03.2011
BG02.06.2011
GR03.06.2011
Former [2011/37]CY02.03.2011
FI02.03.2011
LT02.03.2011
LV02.03.2011
SI02.03.2011
BG02.06.2011
GR03.06.2011
Former [2011/36]LT02.03.2011
LV02.03.2011
GR03.06.2011
Cited inInternational search[A]US2003072757  (FARESE ROBERT V [US], et al) [A] 1-9 * example -; claim - *;
 [DA]WO2004047755  (TULARIK INC [US], et al) [DA] 1-9 * page 1, paragraph 1 - page 3, paragraph 9; example -; claim - *;
 [DA]WO2004100881  (BAYER PHARMACEUTICALS CORP [US], et al) [DA] 1-9 * page 1, line 1 - page 2, line 2; example -; claim - *;
 [A]US2005070545  (FOX BRIAN M [US], et al) [A] 1-9 * page 1, paragraph 2 - paragraph 7; example -; claim - *;
 [PA]WO2006064189  (ASTRAZENECA AB [SE], et al) [PA] 1-9* page 1 - page 2; example -; claim - *;
 [PA]WO2006134317  (ASTRAZENECA AB [SE], et al) [PA] 1-9 * page 1 - page 2; example -; claim - *;
 [A]  - S. N. SAWHNEY ET. AL., "Synthesis of some 2-(5-substituted 1,3,4-oxadiazol-2-yl)-, 2-(5-substituted 1,3,4-thiadiazol-2-yl)- and 2-(3-mercapto-4-substituted- 4H-1,2,4-triazol-5-yl)- benzimidazoles as potential antiinflammatory agents.", INDIAN JOURNAL OF CHEMISTRY SECTION B, (1991), vol. 30B, pages 407 - 412, XP009089706 [A] 1-9 * page 407, formula III; page 411, table 2, compounds IIId and IIIe *
by applicantJP2004067635
 WO2004047755
 WO2004100881
 WO2005013907
    - SMITH, "Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT", NATURE GENETICS, (2000), vol. 25, pages 87 - 90
    - CHEN, "Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase", J. CLIN. INVEST, (2002), vol. 109, pages 1049 - 1055
    - J. CLIN. INVEST., vol. 111, pages 1715 - 1722
    - SAWHNEY; GUPTA, INDIAN JOURNAL OF CHEMISTRY, (1991), vol. 30B, pages 407 - 412
 WO2005GB04726
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.